Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

NCT07145931 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer Squamous Cell Carcinoma
Skull Base--Cancer
Neoadjuvant Chemoimmunotherapy
Objective Response Rate

Interventions

PROCEDURE: Neoadjuvant chemoimmunotherapy
DRUG: Tislelizumab Nab paclitaxel

Sponsor

Sun Yat-sen University